Immune-related bone marrow failure following anti-PD1 therapy

Eur J Cancer. 2017 Jul:80:1-4. doi: 10.1016/j.ejca.2017.04.004. Epub 2017 May 17.
No abstract available

Keywords: Anti-PD1 therapy; Aplastic anaemia; Bone marrow failure; Emergent adverse event; Immune-related adverse event.

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Adenocarcinoma / drug therapy
  • Adenocarcinoma / pathology
  • Adenocarcinoma of Lung
  • Aged
  • Anemia, Aplastic / chemically induced
  • Anemia, Aplastic / complications
  • Antibodies, Monoclonal / adverse effects*
  • Antibodies, Monoclonal / therapeutic use
  • Antibodies, Monoclonal, Humanized / adverse effects*
  • Antibodies, Monoclonal, Humanized / therapeutic use
  • Bone Marrow / drug effects*
  • Bone Marrow / immunology
  • Fatal Outcome
  • Female
  • Humans
  • Lung Neoplasms / drug therapy
  • Lung Neoplasms / pathology
  • Male
  • Nivolumab
  • Pancytopenia / chemically induced*
  • Pancytopenia / complications
  • Programmed Cell Death 1 Receptor / antagonists & inhibitors
  • Programmed Cell Death 1 Receptor / immunology*
  • Severity of Illness Index

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • PDCD1 protein, human
  • Programmed Cell Death 1 Receptor
  • Nivolumab